Cargando…

Psychiatric morbidity associated with screening for breast cancer.

The 28-item GHQ was used to assess psychiatric morbidity in 302 women attending for routine breast cancer screening, 300 women attending for further investigation of a positive screening result and 150 women referred for investigation of breast symptoms. The GHQ-28 was administered on arrival at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellman, R., Angeli, N., Christians, A., Moss, S., Chamberlain, J., Maguire, P.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247323/
https://www.ncbi.nlm.nih.gov/pubmed/2803955
_version_ 1782150957368344576
author Ellman, R.
Angeli, N.
Christians, A.
Moss, S.
Chamberlain, J.
Maguire, P.
author_facet Ellman, R.
Angeli, N.
Christians, A.
Moss, S.
Chamberlain, J.
Maguire, P.
author_sort Ellman, R.
collection PubMed
description The 28-item GHQ was used to assess psychiatric morbidity in 302 women attending for routine breast cancer screening, 300 women attending for further investigation of a positive screening result and 150 women referred for investigation of breast symptoms. The GHQ-28 was administered on arrival at the relevant clinic and three months later. Medical records were used to determine the outcome of the clinic attendance. Women were classified into routinely screened women, women with false positive screening results, symptomatic women with a benign diagnosis, newly diagnosed cancer patients and previously treated cancer patients. When tested on arrival at the clinic, 25% of routinely screened, 30% of women with false positive results and 35% of symptomatic women with benign conditions were probable cases of psychiatric morbidity. The only statistically significant difference was between the routinely screened and symptomatic benign groups. Levels of anxiety were significantly higher in those with false positive results and in the symptomatic benign group than in the routinely screened. Three months later the prevalence of probable psychiatric morbidity had fallen to 19% in both the routinely screened and those with false positive results but remained significantly higher in the symptomatic benign group (31%). Probable cases of psychiatric morbidity among newly detected cancer patients rose from 34 to 46% over the 3-month period. Among women who had had breast cancer diagnosed in the past prevalence remained at 21%. The prevalence of probable psychiatric morbidity in screened women is similar to that in the general population. Among women referred for further investigation because of a false positive screening result prevalence was only slightly increased and there was no evidence of a sustained increase in anxiety. Provided that delays are kept to a minimum and that women are kept informed, a breast cancer screening programme does not increase psychiatric morbidity. Further research is required in cancer patients to determine whether those diagnosed in asymptomatic women have a higher and more sustained degree of psychiatric morbidity than those diagnosed in women who are aware of symptoms.
format Text
id pubmed-2247323
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22473232009-09-10 Psychiatric morbidity associated with screening for breast cancer. Ellman, R. Angeli, N. Christians, A. Moss, S. Chamberlain, J. Maguire, P. Br J Cancer Research Article The 28-item GHQ was used to assess psychiatric morbidity in 302 women attending for routine breast cancer screening, 300 women attending for further investigation of a positive screening result and 150 women referred for investigation of breast symptoms. The GHQ-28 was administered on arrival at the relevant clinic and three months later. Medical records were used to determine the outcome of the clinic attendance. Women were classified into routinely screened women, women with false positive screening results, symptomatic women with a benign diagnosis, newly diagnosed cancer patients and previously treated cancer patients. When tested on arrival at the clinic, 25% of routinely screened, 30% of women with false positive results and 35% of symptomatic women with benign conditions were probable cases of psychiatric morbidity. The only statistically significant difference was between the routinely screened and symptomatic benign groups. Levels of anxiety were significantly higher in those with false positive results and in the symptomatic benign group than in the routinely screened. Three months later the prevalence of probable psychiatric morbidity had fallen to 19% in both the routinely screened and those with false positive results but remained significantly higher in the symptomatic benign group (31%). Probable cases of psychiatric morbidity among newly detected cancer patients rose from 34 to 46% over the 3-month period. Among women who had had breast cancer diagnosed in the past prevalence remained at 21%. The prevalence of probable psychiatric morbidity in screened women is similar to that in the general population. Among women referred for further investigation because of a false positive screening result prevalence was only slightly increased and there was no evidence of a sustained increase in anxiety. Provided that delays are kept to a minimum and that women are kept informed, a breast cancer screening programme does not increase psychiatric morbidity. Further research is required in cancer patients to determine whether those diagnosed in asymptomatic women have a higher and more sustained degree of psychiatric morbidity than those diagnosed in women who are aware of symptoms. Nature Publishing Group 1989-11 /pmc/articles/PMC2247323/ /pubmed/2803955 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Ellman, R.
Angeli, N.
Christians, A.
Moss, S.
Chamberlain, J.
Maguire, P.
Psychiatric morbidity associated with screening for breast cancer.
title Psychiatric morbidity associated with screening for breast cancer.
title_full Psychiatric morbidity associated with screening for breast cancer.
title_fullStr Psychiatric morbidity associated with screening for breast cancer.
title_full_unstemmed Psychiatric morbidity associated with screening for breast cancer.
title_short Psychiatric morbidity associated with screening for breast cancer.
title_sort psychiatric morbidity associated with screening for breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247323/
https://www.ncbi.nlm.nih.gov/pubmed/2803955
work_keys_str_mv AT ellmanr psychiatricmorbidityassociatedwithscreeningforbreastcancer
AT angelin psychiatricmorbidityassociatedwithscreeningforbreastcancer
AT christiansa psychiatricmorbidityassociatedwithscreeningforbreastcancer
AT mosss psychiatricmorbidityassociatedwithscreeningforbreastcancer
AT chamberlainj psychiatricmorbidityassociatedwithscreeningforbreastcancer
AT maguirep psychiatricmorbidityassociatedwithscreeningforbreastcancer